Literature DB >> 10411808

Second-trimester maternal serum inhibin A concentration as an early marker for preeclampsia.

J Aquilina1, A Barnett, O Thompson, K Harrington.   

Abstract

OBJECTIVE: Maternal serum inhibin A concentration is elevated in established preeclampsia. The aim of this study was to investigate whether this relationship antedates the appearance of the classic signs of preeclampsia. STUDY
DESIGN: A retrospective analysis was performed on trisomy 21 screening data from 685 women at between 15 and 19 weeks' gestation. The main outcome measures were preeclampsia and small for gestational age (<5th percentile) infants.
RESULTS: Preeclampsia developed in 35 women (5.5%). Women with inhibin A concentration >2.0 multiples of the median were significantly more likely to acquire preeclampsia (P <.00001) and to be delivered of a small for gestational age infant (<5th percentile, P <.00001) than were women with inhibin A concentration </=2.0 multiples of the median. The odds ratios were 9.4 (95% confidence interval 4.6-19.3) for development of preeclampsia and 18.2 (95% confidence interval 6. 0-54.8) for preeclampsia necessitating delivery at <37 weeks' gestation. The association remained statistically significant for nulliparous women.
CONCLUSION: Elevated maternal inhibin A concentration in the second trimester was strongly associated with a subsequent risk of preeclampsia. The potential role of second trimester inhibin A measurement in a screening strategy for preeclampsia needs to be investigated further.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411808     DOI: 10.1016/s0002-9378(99)70448-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

Review 1.  Pathophysiology and maternal biologic markers of preeclampsia.

Authors:  Jacques Massé; Yves Giguère; Abdelaziz Kharfi; Joël Girouard; Jean-Claude Forest
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

2.  Multifactorial analysis of affinity-mass spectrometry data from serum protein samples: a strategy to distinguish patients with preeclampsia from matching control individuals.

Authors:  Ulrich Pecks; Franka Seidenspinner; Claudia Röwer; Toralf Reimer; Werner Rath; Michael O Glocker
Journal:  J Am Soc Mass Spectrom       Date:  2010-01-04       Impact factor: 3.109

3.  Umbilical Vein and Maternal Serum Inhibin A, Activin A, and Follistatin Concentrations in IUGR due to Placental Dysfunction Pregnancies.

Authors:  Sravanthi Kasam; Zongji Shen; Hui Cao; Madisetty Venkat Sudeep
Journal:  J Obstet Gynaecol India       Date:  2013-04-16

4.  The 769G>A variant of the inhibin-alpha gene in Korean patients with preeclampsia.

Authors:  S Y Kim; J-H Lim; J-H Yang; M-Y Kim; M-H Kim; S-Y Park; H-M Ryu
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

5.  Maternal serum and amniotic fluid inhibin A levels in women who subsequently develop severe preeclampsia.

Authors:  Shin-Young Kim; Hyun-Mee Ryu; Jae-Hyug Yang; Moon-Young Kim; Hyun-Kyong Ahn; Joong-Sik Shin; Jun-Seek Choi; So-Yeon Park; Jin-Mi Kim; Bom-Yi Lee; Do-Jin Kim
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

Review 6.  Novel biomarkers for predicting preeclampsia.

Authors:  David M Carty; Christian Delles; Anna F Dominiczak
Journal:  Trends Cardiovasc Med       Date:  2008-07       Impact factor: 6.677

7.  Quantification and Application of Potential Epigenetic Markers in Maternal Plasma of Pregnancies with Hypertensive Disorders.

Authors:  Hyun Jin Kim; Shin Young Kim; Ji Hyae Lim; Dong Wook Kwak; So Yeon Park; Hyun Mee Ryu
Journal:  Int J Mol Sci       Date:  2015-12-15       Impact factor: 5.923

8.  Fibrinogen-Like Protein 2-Associated Transcriptional and Histopathological Features of Immunological Preeclampsia.

Authors:  Pascale Robineau-Charette; David Grynspan; Samantha J Benton; Jeremiah Gaudet; Brian J Cox; Barbara C Vanderhyden; Shannon A Bainbridge
Journal:  Hypertension       Date:  2020-07-27       Impact factor: 10.190

9.  Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory.

Authors:  Jean-Antoine Ribeil; Myriam Labopin; Aurélie Stanislas; Benjamin Deloison; Delphine Lemercier; Anoosha Habibi; Souha Albinni; Caroline Charlier; Olivier Lortholary; François Lefrere; Mariane De Montalembert; Stéphane Blanche; Frédéric Galactéros; Jean-Marc Tréluyer; Eliane Gluckman; Yves Ville; Laure Joseph; Marianne Delville; Alexandra Benachi; Marina Cavazzana
Journal:  Am J Hematol       Date:  2018-04-17       Impact factor: 10.047

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.